{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T02:30:34Z","timestamp":1788489034001,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,7]],"date-time":"2016-07-07T00:00:00Z","timestamp":1467849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.bcp.2016.06.019","type":"journal-article","created":{"date-parts":[[2016,7,3]],"date-time":"2016-07-03T10:11:57Z","timestamp":1467540717000},"page":"22-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy"],"prefix":"10.1016","volume":"116","author":[{"given":"Chong","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyan","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changshan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiquan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuning","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianping","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2016.06.019_b0005","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1200\/JCO.2007.11.0593","article-title":"Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer","volume":"25","author":"Hsu","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2016.06.019_b0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","article-title":"Molecular mechanisms of resistance and toxicity associated with platinating agents","volume":"33","author":"Rabik","year":"2007","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bcp.2016.06.019_b0015","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1021\/cr980421n","article-title":"Structure, recognition, and processing of cisplatin-DNA adducts","volume":"99","author":"Jamieson","year":"1999","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bcp.2016.06.019_b0020","first-page":"227","article-title":"Cellular and molecular pharmacology of oxaliplatin","volume":"1","author":"Raymond","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2016.06.019_b0025","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"New Engl. J. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.bcp.2016.06.019_b0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0305-7372(03)00081-1","article-title":"The proteasome: structure, function, and role in the cell","volume":"29","author":"Adams","year":"2003","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bcp.2016.06.019_b0035","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrm2731","article-title":"Breaking the chains: structure and function of the deubiquitinases","volume":"10","author":"Komander","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2016.06.019_b0040","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1038\/onc.2011.443","article-title":"Deubiquitinases in cancer: new functions and therapeutic options","volume":"31","author":"Fraile","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2016.06.019_b0045","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.4161\/cc.8.11.8739","article-title":"DUBs and cancer: the role of deubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors","volume":"8","author":"Hussain","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bcp.2016.06.019_b0050","doi-asserted-by":"crossref","first-page":"7781","DOI":"10.1074\/jbc.M112.441907","article-title":"Ubiquitinated proteins activate the proteasomal ATPases by binding to Usp14 or Uch37 homologs","volume":"288","author":"Peth","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2016.06.019_b0055","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev.biochem.78.081507.101607","article-title":"Recognition and processing of ubiquitin-protein conjugates by the proteasome","volume":"78","author":"Finley","year":"2009","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bcp.2016.06.019_b0060","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1158\/1078-0432.CCR-14-0568","article-title":"Molecular pathways: translational potential of deubiquitinases as drug targets","volume":"20","author":"D\u2019Arcy","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2016.06.019_b0065","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1126\/science.292.5521.1552","article-title":"Impairment of the ubiquitin-proteasome system by protein aggregation","volume":"292","author":"Bence","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.bcp.2016.06.019_b0070","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1038\/cr.2010.123","article-title":"Physiological levels of ATP negatively regulate proteasome function","volume":"20","author":"Huang","year":"2010","journal-title":"Cell Res."},{"key":"10.1016\/j.bcp.2016.06.019_b0075","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1002\/ijc.24195","article-title":"Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo","volume":"124","author":"Yang","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcp.2016.06.019_b0080","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.18632\/oncotarget.2113","article-title":"Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth","volume":"5","author":"Liu","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2016.06.019_b0085","article-title":"L-carnitine is an endogenous HDAC inhibitor selectively inhibiting cancer cell growth in vivo and in vitro","volume":"7","author":"Huang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2016.06.019_b0090","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1158\/1078-0432.CCR-13-1063","article-title":"Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation","volume":"20","author":"Shi","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2016.06.019_b0095","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ejphar.2011.02.043","article-title":"Shikonin extracted from medicinal Chinese herbs exerts anti-inflammatory effect via proteasome inhibition","volume":"658","author":"Lu","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2016.06.019_b0100","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/bip.10001","article-title":"Spectroscopic studies of interaction of chlorobenzylidine with DNA","volume":"62","author":"Zhong","year":"2001","journal-title":"Biopolymers"},{"key":"10.1016\/j.bcp.2016.06.019_b0105","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1089\/dna.2010.1054","article-title":"Spectroscopic studies on the interaction of isatin with calf thymus DNA","volume":"29","author":"Kashanian","year":"2010","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.bcp.2016.06.019_b0110","first-page":"103","article-title":"[Studies on the interaction mode between polymyxin B sulfate and DNA with EB as a fluorescence probe]","volume":"22","author":"Jiang","year":"2002","journal-title":"Guang pu xue yu guang pu fen xi = Guang pu"},{"key":"10.1016\/j.bcp.2016.06.019_b0115","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.asr.2008.10.011","article-title":"Gamma-H2AX as a biomarker of DNA damage induced by ionizing radiation in human peripheral blood lymphocytes and artificial skin","volume":"43","author":"Redon","year":"2009","journal-title":"Adv Space Res."},{"key":"10.1016\/j.bcp.2016.06.019_b0120","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1038\/srep05240","article-title":"A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases","volume":"4","author":"Liu","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2016.06.019_b0125","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1038\/sj.emboj.7600832","article-title":"Structure and mechanisms of the proteasome-associated deubiquitinating enzyme USP14","volume":"24","author":"Hu","year":"2005","journal-title":"EMBO J."},{"key":"10.1016\/j.bcp.2016.06.019_b0130","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1111\/j.1742-4658.2011.08393.x","article-title":"Crystal structure of the catalytic domain of UCHL5, a proteasome-associated human deubiquitinating enzyme, reveals an unproductive form of the enzyme","volume":"278","author":"Maiti","year":"2011","journal-title":"FEBS J."},{"key":"10.1016\/j.bcp.2016.06.019_b0135","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.bcp.2010.06.018","article-title":"LW6, a novel HIF-1 inhibitor, promotes proteasomal degradation of HIF-1alpha via upregulation of VHL in a colon cancer cell line","volume":"80","author":"Lee","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2016.06.019_b0140","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1741-7007-8-153","article-title":"Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cells","volume":"8","author":"Rico-Bautista","year":"2010","journal-title":"BMC Biol."},{"key":"10.1016\/j.bcp.2016.06.019_b0145","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1124\/mol.114.092114","article-title":"Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib)","volume":"86","author":"Niewerth","year":"2014","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2016.06.019_b0150","doi-asserted-by":"crossref","first-page":"10425","DOI":"10.1158\/0008-5472.CAN-06-2126","article-title":"Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity","volume":"66","author":"Chen","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2016.06.019_b0155","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1158\/0008-5472.CAN-06-3546","article-title":"Clioquinol, a therapeutic agent for Alzheimer\u2019s disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts","volume":"67","author":"Chen","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2016.06.019_b0160","doi-asserted-by":"crossref","first-page":"6256","DOI":"10.1021\/jm8007807","article-title":"Ni(II), Cu(II), and Zn(II) diethyldithiocarbamate complexes show various activities against the proteasome in breast cancer cells","volume":"51","author":"Cvek","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2016.06.019_b0165","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.jinorgbio.2011.09.013","article-title":"Effects of tethered ligands and of metal oxidation state on the interactions of cobalt complexes with the 26S proteasome","volume":"105","author":"Tomco","year":"2011","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.bcp.2016.06.019_b0170","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00775-008-0358-7","article-title":"Potent in vitro anti-Trypanosoma cruzi activity of pyridine-2-thiol N-oxide metal complexes having an inhibitory effect on parasite-specific fumarate reductase","volume":"13","author":"Vieites","year":"2008","journal-title":"J. Biol. Inorg. Chem."},{"key":"10.1016\/j.bcp.2016.06.019_b0175","doi-asserted-by":"crossref","first-page":"6572","DOI":"10.1074\/jbc.M707568200","article-title":"ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis","volume":"283","author":"Pabla","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2016.06.019_b0180","doi-asserted-by":"crossref","first-page":"9265","DOI":"10.1158\/0008-5472.CAN-10-1530","article-title":"Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis","volume":"70","author":"Kapuria","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2016.06.019_b0185","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/nm.2536","article-title":"Inhibition of proteasome deubiquitinating activity as a new cancer therapy","volume":"17","author":"D\u2019Arcy","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2016.06.019_b0190","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1158\/1535-7163.MCT-12-1057","article-title":"Deubiquitinase inhibition of 19S regulatory particles by 4-arylidene curcumin analog AC17 causes NF-kappaB inhibition and p53 reactivation in human lung cancer cells","volume":"12","author":"Zhou","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2016.06.019_b0195","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1158\/1078-0432.CCR-13-2658","article-title":"Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses","volume":"20","author":"Coughlin","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2016.06.019_b0200","article-title":"Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15","author":"Wang","year":"2015","journal-title":"Chem. Biol. Drug. Des."},{"key":"10.1016\/j.bcp.2016.06.019_b0205","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature09299","article-title":"Enhancement of proteasome activity by a small-molecule inhibitor of USP14","volume":"467","author":"Lee","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2016.06.019_b0210","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1158\/0008-5472.CAN-05-2321","article-title":"Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis","volume":"66","author":"Bazzaro","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2016.06.019_b0215","doi-asserted-by":"crossref","first-page":"7340","DOI":"10.1158\/1078-0432.CCR-08-0642","article-title":"Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor","volume":"14","author":"Bazzaro","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2016.06.019_b0220","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature10167","article-title":"Selective killing of cancer cells by a small molecule targeting the stress response to ROS","volume":"475","author":"Raj","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2016.06.019_b0225","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.celrep.2012.11.023","article-title":"Gambogic acid is a tissue-specific proteasome inhibitor in vitro and in vivo","volume":"3","author":"Li","year":"2013","journal-title":"Cell Rep."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295216301642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295216301642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T15:22:19Z","timestamp":1536592939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295216301642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":45,"alternative-id":["S0006295216301642"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2016.06.019","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2016.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}